Stefania De Lorenzo

1.4k total citations
48 papers, 875 citations indexed

About

Stefania De Lorenzo is a scholar working on Oncology, Surgery and Hepatology. According to data from OpenAlex, Stefania De Lorenzo has authored 48 papers receiving a total of 875 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 23 papers in Surgery and 19 papers in Hepatology. Recurrent topics in Stefania De Lorenzo's work include Cholangiocarcinoma and Gallbladder Cancer Studies (18 papers), Hepatocellular Carcinoma Treatment and Prognosis (17 papers) and Cancer Mechanisms and Therapy (9 papers). Stefania De Lorenzo is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (18 papers), Hepatocellular Carcinoma Treatment and Prognosis (17 papers) and Cancer Mechanisms and Therapy (9 papers). Stefania De Lorenzo collaborates with scholars based in Italy, United States and France. Stefania De Lorenzo's co-authors include Giovanni Brandi, Francesco Tovoli, Andrea Palloni, Alessandro Rizzo, Giorgio Frega, Simona Tavolari, Franco Trevisani, Angela Dalia Ricci, Francesca Abbati and Maria A. Pantaleo and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Annals of Oncology.

In The Last Decade

Stefania De Lorenzo

46 papers receiving 866 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stefania De Lorenzo Italy	16	403	386	243	231	185	48	875
Nicolò Bassi Italy	17	471 1.2×	361 0.9×	179 0.7×	167 0.7×	184 1.0×	33	921
Isabella Lurje Germany	14	444 1.1×	229 0.6×	277 1.1×	207 0.9×	205 1.1×	32	877
Jingmei Lin United States	18	375 0.9×	371 1.0×	136 0.6×	173 0.7×	196 1.1×	82	1.1k
M. Henar Alonso United States	19	397 1.0×	361 0.9×	214 0.9×	220 1.0×	179 1.0×	42	1.0k
Masaru Inagaki Japan	15	417 1.0×	302 0.8×	189 0.8×	155 0.7×	312 1.7×	115	952
Yidong Cai China	7	358 0.9×	263 0.7×	118 0.5×	223 1.0×	222 1.2×	9	815
Sylvain Kirzin France	18	560 1.4×	699 1.8×	109 0.4×	244 1.1×	218 1.2×	41	1.2k
Hideaki Yano Japan	17	496 1.2×	332 0.9×	168 0.7×	169 0.7×	115 0.6×	66	1.0k
Gregory Kouraklis Greece	17	228 0.6×	191 0.5×	168 0.7×	142 0.6×	210 1.1×	43	822
Motofumi Tanaka Japan	15	212 0.5×	331 0.9×	374 1.5×	119 0.5×	231 1.2×	75	888

Countries citing papers authored by Stefania De Lorenzo

Since Specialization

Citations

This map shows the geographic impact of Stefania De Lorenzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefania De Lorenzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefania De Lorenzo more than expected).

Fields of papers citing papers by Stefania De Lorenzo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefania De Lorenzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefania De Lorenzo. The network helps show where Stefania De Lorenzo may publish in the future.

Co-authorship network of co-authors of Stefania De Lorenzo

This figure shows the co-authorship network connecting the top 25 collaborators of Stefania De Lorenzo. A scholar is included among the top collaborators of Stefania De Lorenzo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefania De Lorenzo. Stefania De Lorenzo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Rusi, et al.. (2024). Combination makes strength: a narrative review of transarterial radioembolization plus immune checkpoint inhibitors for hepatocellular carcinoma. Chinese Clinical Oncology. 13(5). 71–71. 1 indexed citations

Garajová, Ingrid, Fabio Gelsomino, Massimiliano Salati, et al.. (2023). Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain?. Life. 13(11). 2170–2170. 1 indexed citations

Garajová, Ingrid, Fabio Gelsomino, Massimiliano Salati, et al.. (2023). Bone Metastases from Intrahepatic Cholangiocarcinoma Confer Worse Prognosis. Current Oncology. 30(3). 2613–2624. 4 indexed citations

Lorenzo, Stefania De, Ingrid Garajová, Bernardo Stefanini, & Francesco Tovoli. (2021). Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development. Expert Opinion on Investigational Drugs. 30(7). 759–772. 12 indexed citations

Tovoli, Francesco, Ingrid Garajová, Fabio Gelsomino, et al.. (2021). Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second‐line clinical trials. Liver International. 42(2). 458–467. 7 indexed citations

Brandi, Giovanni, Angela Dalia Ricci, Alessandro Rizzo, et al.. (2020). Is post‐transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases?. Cancer Communications. 40(9). 461–464. 46 indexed citations

Lorenzo, Stefania De, Francesco Tovoli, Alessandro Mazzotta, et al.. (2020). Non-Alcoholic Steatohepatitis as a Risk Factor for Intrahepatic Cholangiocarcinoma and Its Prognostic Role. Cancers. 12(11). 3182–3182. 40 indexed citations

Brandi, Giovanni, Alessandro Rizzo, Valeria Relli, et al.. (2020). Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster. BMC Medical Genetics. 21(1). 225–225. 5 indexed citations

Rizzo, Alessandro, Angela Dalia Ricci, Andrea Palloni, et al.. (2020). Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow. Anticancer Research. 40(6). 3013–3030. 63 indexed citations

10.

Marco, Mariacristina Di, Riccardo Carloni, Stefania De Lorenzo, et al.. (2020). Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report. World Journal of Gastrointestinal Oncology. 12(12). 1456–1463. 2 indexed citations

11.

Tovoli, Francesco, Stefania De Lorenzo, & Franco Trevisani. (2020). Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?. Vaccines. 8(4). 578–578. 18 indexed citations

12.

Tovoli, Francesco, Vincenzo Dadduzio, Stefania De Lorenzo, et al.. (2020). 999P Real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma. Annals of Oncology. 31. S695–S695. 3 indexed citations

13.

Ricci, Angela Dalia, Alessandro Rizzo, Simona Tavolari, et al.. (2020). Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis. Anticancer Research. 40(2). 597–608. 25 indexed citations

14.

Carloni, Riccardo, Stefania De Lorenzo, Elisa Grassi, et al.. (2020). Aggressive approach to metastatic pancreatic cystadenocarcinoma in a patient harboring BRCA-1 germline mutation: a case report.. Pancreatology. 20. S149–S150.

15.

Palloni, Andrea, Giorgio Frega, Francesca Abbati, et al.. (2019). An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone. Anti-Cancer Drugs. 30(4). 428–430. 1 indexed citations

16.

Ielasi, Luca, Vito Sansone, Alessandro Granito, et al.. (2018). An update of treatments of hepatocellular carcinoma in patientsrefractory to sorafenib. Drugs of today. 54(10). 615–615. 7 indexed citations

17.

Lorenzo, Stefania De, Francesco Tovoli, Maria Aurelia Barbera, et al.. (2018). Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept. Scientific Reports. 8(1). 9997–9997. 83 indexed citations

18.

Brandi, Giovanni, Stefania De Lorenzo, Marco Candela, et al.. (2017). Microbiota, NASH, HCC and the potential role of probiotics. Carcinogenesis. 38(3). 231–240. 125 indexed citations

19.

Ravaioli, Matteo, Alessandro Cucchetti, Antonio Daniele Pinna, et al.. (2017). The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation. Scientific Reports. 7(1). 11305–11305. 14 indexed citations

20.

Trevisani, Franco, Giovanni Brandi, Francesca Garuti, et al.. (2017). Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. Journal of Cancer Research and Clinical Oncology. 144(2). 403–414. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact